Aarti Pharmalabs Ltd Board Meeting

571.25
(-1.18%)
Jul 23, 2024|03:32:50 PM

Aarti Pharma CORPORATE ACTIONS

24/07/2023calendar-icon
23/07/2024calendar-icon
PurposeBoard Meetings DateAnnouncement Date
Board Meeting13 May 20244 May 2024
Aarti Pharmalabs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/05/2024 inter alia to consider and approve Audited Financial Results for the quarter ended March 31 2024; Audited Financial Statements for the year ended March 31 2024; Recommend Final Dividend if any for the year ended March 31 2024; Approve any other business matter if required with the permission of Chair. Outcome of Board Meeting Appointment of Auditors (As Per BSE Announcement dated on 13.05.2024)
Board Meeting7 Feb 202430 Jan 2024
Aarti Pharmalabs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/02/2024 inter alia to consider and approve Audited Financial Results for the quarter and nine months ended December 31 2023 Interim Dividend if any for the FY 2023-24 and other business matters if any. Interim Dividend for FY 2023-24 Financial results and Interim dividend Audited Standalone and Consolidated Financial Results for the quarter and nine months ended December 31, 2023 Record date for Interim dividend (As Per BSE Announcement Dated on 07.02.2024)
Board Meeting7 Nov 202330 Oct 2023
Aarti Pharmalabs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/11/2023 inter alia to consider and approve Audited Financial Results for the quarter and half year ended September 30 2023 and Any other business matter if any Financial Results for the quarter and half year ended September 30, 2023 (As per BSE Announcement Dated on 07/11/2023)
Board Meeting5 Aug 202328 Jul 2023
Aarti Pharmalabs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/08/2023 inter alia to consider and approve Audited Financial Results and any other Business Matter if required. Outcome of the Board Meeting held on Saturday, August 05, 2023. (As Per BSE Announcement Dated on 05.08.2023)

Aarti Pharma: Related News

No record found

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Knowledge Centerplus
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Securities Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Knowledge Centerplus

Follow us on

facebooktwitterrssyoutubeinstagramlinkedin

2024, IIFL Securities Ltd. All Rights Reserved

ATTENTION INVESTORS
  • Prevent Unauthorized Transactions in your demat / trading account Update your Mobile Number/ email Id with your stock broker / Depository Participant. Receive information of your transactions directly from Exchanges on your mobile / email at the end of day and alerts on your registered mobile for all debits and other important transactions in your demat account directly from NSDL/ CDSL on the same day." - Issued in the interest of investors.
  • KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
  • No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."

www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.

RISK DISCLOSURE ON DERIVATIVES
  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to Rs. 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Copyright © IIFL Securities Ltd. All rights Reserved.

Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248

plus
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.